合成生物产品制造商Twist Bioscience(TWST)周一盘中大涨19.27%,引发了市场的广泛关注。
公司上周公布的2023财年第四财季数据优于市场预期,成为这一上涨行情的主因。数据显示,TWST在这一财季实现营收8470万美元,高于街坊预期的8220万美元。净亏损59美分/股,也好于预期的71美分亏损。
除了上佳的财报数据,市场对TWST的未来前景也充满期待。公司预计2025财年全年收入将达到3.67亿至3.77亿美元,中值达到3.714亿美元。其中2025财年第一季度营收预计约为8700万美元。目前TWST已是合成生命科学领域的领头企业,产品遍布全球65多个国家和地区,未来发展空间广阔。因此,投资者对其长期增长前景也加大了信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.